How LIR Life Sciences is making GLP-1 therapy easier to access worldwide

This content was created by Hive Labs in partnership with Fairfax Partners on behalf of LIR Life Sciences Corp.

Treating obesity isn’t always as simple as telling someone to lose weight, and with the World Obesity Federation estimating that nearly four billion people worldwide will be affected by overweight and obesity by 2035, the need for accessible and innovative treatment is more apparent than ever.

Vancouver-based LIR Life Sciences Corp. is a leader in the development, research, and advancement of novel, needle-free drug delivery platforms for obesity treatment across global markets. The local biotechnology company leverages FDA-approved compounds with innovative delivery mechanisms, and simply put, it has the power to change the way we treat obesity. Here’s how.

A needle-free solution

LIR Life Sciences Corp.

GLP-1/GIP therapies have certainly had a surge in popularity over the last few years, which is great, unless you don’t like needles. And frankly, that’s a lot of the population.

LIR’s transdermal GLP-1 delivery isn’t a needle – it’s a patch. This innovative solution eliminates the discomfort and injection barriers that accompany needles, making the treatment more accessible to people who may have otherwise avoided it.

No refrigeration

LIR Life Sciences Corp.

Another element of injectable GLP-1 delivery that’s often overlooked is storage. More specifically, refrigeration. For many, refrigerating injections is a non-issue; however, it may not always be available for people living in hot climates and underserved regions.

Because the patch doesn’t need to be refrigerated, there’s more flexibility with where a person can store it. It’s also more convenient for travel, because no one wants to use a cooler as their carry-on.

Cultivating convenience

LIR Life Sciences Corp.

If you experience side effects from an injection, you’re out of luck until it exits your system. If you experience side effects from a patch, you just take it off. Plus, when you consider that current injectable treatments average ~$12,000 a year, any sort of price reduction is incredibly welcome.

LIR Life Science is advancing obesity treatment with an exclusive novel platform delivery system, developing scalable solutions to expand patient access and improve long-term outcomes. To learn more about the groundbreaking science happening right here in Vancouver and get information about investing, visit the LIR website.